Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions "CAVAD"

Completed

Phase 4 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 5 May 2015.

1 Mar 2008 17 Feb 2009 1 May 2011 1 Jun 2011 1 Dec 2009 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Parallel Assignment

Contacts

Not available